D-penicillamine -induced

Tournade, H., et al., (1990) D-penicillamine-induced autoimmunity in Brown-Norway rats. Similarities with HgC12-induced autoimmunity. J. Immunol.,144, 2985, 1990... [Pg.481]

Qasim, F.J., Thiru, S., and Gillespie, K.,Gold and D-penicillamine induce vasculitis and up-regulate mRNA for IL-4 in the Brown Norway rat Support for a role for Th2 cell activity. Clin. Exp. Immunol., 108,438, 1997... [Pg.481]

Brik, R. et al., D-penicillamine-induced autoantibodies in a mouse model. Clin. Exp. Rheumatol., 13, 483, 1995. [Pg.483]

Robinson, C.J., Balazs, T., and Egorov, I.K., Mercuric chloride-, gold sodium thiomalate-, and D-penicillamine-induced antinuclear antibodies in mice. Toxicol. Appl. Pharmacol., 86, 159, 1986. [Pg.483]

Although rare, cases of renal lupus syndrome and pemphigus blisters have also been reported as a consequence of D-penicillamine-induced immune complexes (Ntoso et al., 1986 Bigazzi, 1988), as well as with other drugs. With renal lupus syndrome, secondary glomerulonephritis may result if granular IgG antibodies are produced and deposited on the basement membranes. In patients with pemphigus blisters, autoantibodies to the intercellular substance of the skin have been recovered from the sera, and dermal biopsies have demonstrated intracellular deposits or... [Pg.558]

Fried Ml, Protheroe DT. D-penicillamine induced myasthenia gravis. Its relevance for the anaesthetist. Br J Anaesth 1986 58(10) 1191-3. [Pg.58]

Blanloeil Y, Baron D, Gazeau MF, Nicolas F. Cnrarisation prolongee an cours d un syndrome myasthenique induit par la D-penicillamine. [Prolonged neuromuscular blockade during D-penicillamine-induced myasthenia.] Anesth Analg (Paris) 1980 37(7-8) 441-3. [Pg.58]

Raynauld JP, Lee YS, Komfeld P, Fries JF. Unilateral ptosis as an initial manifestation of D-penicillamine induced myasthenia gravis. J Rheumatol 1993 20(9) 1592-3. [Pg.1624]

Drosos AA, Christou L, Galanopoulou V, Tzioufas AG, Tsiakou EK. D-penicillamine induced myasthenia gravis clinical, serological and genetic findings. Clin Exp Rheumatol 1993 11(4) 387-91. [Pg.2747]

Petrides PE, Gerhartz HH. D-penicillamine-induced agranulocytosis hematological remission upon treatment with recombinant GM-CSF. Z Rheumatol 1991 50(5) 328-9. [Pg.2750]

Ramboer C, Verhamme M. D-penicillamine-induced oesophageal ulcers. Acta Clin Belg 1989 44(3) 189-91. [Pg.2750]

Kumar A, Bhat A, Gupta DK, Goel A, Malaviya AN. D-penicillamine-induced acute hypersensitivity pnenmoni-tis and cholestatic hepatitis in a patient with rhenmatoid arthritis. Clin Exp Rheumatol 1985 3(4) 337-9. [Pg.2750]

Speerstra F, van de Putte LB, Rasker JJ, Reekers P, Vandenbroucke JP. The relationship between aurothio-glucose- and D-penicillamine-induced proteinuria. Scand J Rheumatol 1984 13(4) 363-8. [Pg.2751]

Isenring P, de Cotret PR, Delage C, Kingma I, Lebel M. d-Penicillamine induced reversible minimal change nephropathy in rheumatoid arthritis. J Nephrol 1991 4 245-8. [Pg.2751]

Karpinski J, Jothy S, Radoux V, Levy M, Baran D. D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature. Am J Nephrol 1997 17(6) 528-32. [Pg.2751]

Enzenauer RJ, West SG, Rubin RL. D-penicillamine-induced lupus erythematosus. Arthritis Rheum 1990 33(10) 1582-5. [Pg.2752]

Dootson G, Sarkany I. D-penicillamine induced dermopa-thy in Wilson s disease. Clin Exp Dermatol 1987 12(l) 66-8. [Pg.2752]

Sahn EE, Maize JC, Garen PD, Mullins SC, Silver RM. D-penicillamine-induced elastosis perforans serpiginosa in a child with juvenile rheumatoid arthritis. Report of a case and review of the literature. J Am Acad Dermatol 1989 20(5 Pt 2) 979-88. [Pg.2753]

Matsushita A, Hiruma M, Ogawa H, Watanabe S, Saeki T. A case of D-penicillamine-induced elastosis perforans serpiginosa in a women with systemic sclerosis. Nishinihon J Dermatol 1999 61 451. ... [Pg.2753]

Penas PF, Buezo GF, Carvajal I, Dauden E, Lopez A, Diaz LA. D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease. J Am Acad Dermatol 1997 37(l) 121-3. [Pg.2753]

Bahmer FA, Bambauer R, Stenger D. Penicillamine-induced pemphigus foliaceus-hke dermatosis. A case with unusual features, successfully treated by plasmapheresis. Arch Dermatol 1985 121(5) 665-8. [Pg.2753]

Takahashi K, Ogita T, Okudaira H, Yoshinoya S, Yoshizawa H, Miyamoto T. D-penicillamine-induced polymyositis in patients with rheumatoid arthritis. Arthritis Rheum 1986 29(4) 560-4. [Pg.2755]

Matsumura T, Yuhara T, Yamane K, Kono I, Kabashima T, Kashiwagi H. D-penicillamine-induced polymyositis occurring in patients with rheumatoid arthritis a report of two cases and demonstration of a positive lymphocyte stimulation test to D-penicillamine. Henry Ford Hosp Med J 1986 34(2) 123-6. [Pg.2755]

Taneja V, Mehra N, Singh YN, Kumar A, Malaviya A, Singh RR. HLA-D region genes and susceptibility to D-penicillamine-induced myositis. Arthritis Rheum 1990 33(9) 1445-7. [Pg.2755]

Ibel H, Feist D, Endres W, Belohradsky BH. D-Penicillamin-induzierter IgA-Mangel bei der Therapie der WUsonschen Erkrankung. [D-penicillamine-induced IgA deficiency in the therapy of Wilson s disease.] Khn Padiatr 1990 202(6) 427-9. [Pg.2755]

Emery P, Panayi GS, Huston G, Welsh KI, Mitchell SC, Shah RR, Idle JR, Smith RL, Waring RH. D-Penicillamine induced toxicity in rheumatoid arthritis the role of sulphoxidation status and HLA-DR3. J Rheumatol 1984 ll(5) 626-32. [Pg.2756]

Seideman P, Ayesh R. Reduced sulphoxidation capacity in D-penicillamine induced myasthenia gravis. Clin Rheumatol 1994 13(3) 435-7. [Pg.2756]

Speerstra F, Reekers P, van de Putte LB, Vandenbroucke JP. HLA associations in aurothioglucose-and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. Tissue Antigens 1985 26(1) 35 0. [Pg.2756]

Seguin B, Masson MJ, Uetrecht J D-penicillamine-induced autoimmunity in the Brown Norway rat role for both T and non-T splenocytes in adoptive transfer of tolerance. Chem ResToxicol 2004 17 1299-302. [Pg.150]

A drug-induced systemic lupus erythematosus (SEE) with proliferative glomerulonephritis has also been described in patients treated with D-penicillamine [111, 157]. Systemic lupus erythematosus syndrome is induced in approximately 2% of patients treated with D-penicillamine [112,158]. Unlike other forms of drug-induced systemic lupus erythematosus, anti-double-strand DNA anhbodies and/or hypocomplementemia are seen in D-penicillamine-induced systemic lupus erythematosus syndrome [111, 156]. Nephropathy is rare in D-penicillamine-induced systemic lupus erythematosus syndrome [111]. Walshe [112] reported that 8 patients developed the serological change of systemic lupus erythematosus of 120 patients with Wilson s disease treated with D-penicillamine, but none of them showed nephropathy. [Pg.467]

Chalmers [111] reported 6 rheumatoid arthritis patients with D-penicillamine-induced systemic lupus erythematosus syndrome. All patients had previous... [Pg.467]

Figure 3. An illustration of the pathogenesis of D-penicillamine induced nephropathy.

Sternlieb I, Bennet B, Scheinberg lEI. D-penicillamine induced Goodpasture s syndrome in Wilson s disease. Ann Intern Med 1975 82 673. [Pg.476]

Billingsley EM, Stevens MB. The relationship between D-penicillamine-induced proteinuria and prior gold nephropathy. Johns Hopkins Med J 1981 148 64-67. [Pg.476]

Matloff DS, Kaplan MM. D-penicillamine-induced Goodpasture s-like syndrome in primary biliary cirrhosis successful treatment with plasmapheresis and immunosuppressives. Gastroenterology 1980 78 1046-1049. [Pg.477]

Devogelaer J-P, Pirson Y, Vandenbroucke J-M, Cosyns J-P, Brichard S, Deuxchaisnes CN. D-penicillamine induced crescentic glomerulonephritis Report and review of the literature. J Rheumatol 1987 14 1036-1041. [Pg.477]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...